Zacks Research Issues Optimistic Forecast for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at Zacks Research upped their Q4 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a research note issued on Tuesday, February 3rd. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $0.32 for the quarter, up from their prior forecast of $0.02. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.03 EPS, FY2026 earnings at ($0.01) EPS, Q2 2027 earnings at $0.08 EPS and Q4 2027 earnings at $0.14 EPS.

A number of other equities research analysts also recently commented on the company. Piper Sandler began coverage on Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Citigroup reissued a “market outperform” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.20.

Esperion Therapeutics Trading Up 6.9%

Shares of ESPR stock opened at $3.40 on Thursday. The stock has a 50 day simple moving average of $3.61 and a 200-day simple moving average of $2.89. The company has a market cap of $812.80 million, a price-to-earnings ratio of -6.80, a price-to-earnings-growth ratio of 0.67 and a beta of 1.09. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The firm had revenue of $87.31 million for the quarter, compared to analyst estimates of $78.33 million.

Insider Activity

In other news, CFO Benjamin Halladay sold 7,337 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares in the company, valued at $1,715,816.75. This represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 15,543 shares of company stock valued at $55,709 in the last quarter. 1.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. DHJJ Financial Advisors Ltd. boosted its stake in shares of Esperion Therapeutics by 209.2% during the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 6,380 shares during the last quarter. KFG Wealth Management LLC purchased a new position in shares of Esperion Therapeutics during the fourth quarter valued at approximately $37,000. Larson Financial Group LLC purchased a new position in shares of Esperion Therapeutics during the fourth quarter valued at approximately $39,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Esperion Therapeutics during the third quarter worth approximately $29,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Esperion Therapeutics by 49.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 3,822 shares during the period. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.